CN103649091A - 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 - Google Patents
取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 Download PDFInfo
- Publication number
- CN103649091A CN103649091A CN201280027509.4A CN201280027509A CN103649091A CN 103649091 A CN103649091 A CN 103649091A CN 201280027509 A CN201280027509 A CN 201280027509A CN 103649091 A CN103649091 A CN 103649091A
- Authority
- CN
- China
- Prior art keywords
- dihydrochloride
- cancer
- mixture
- formula
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PZBCKZWLPGJMAO-UHFFFAOYSA-N COc(c1c(cc2)C3=NCCN3C(NC(c3cnc(N)nc3)=O)=N1)c2OCCCN1CCOCC1 Chemical compound COc(c1c(cc2)C3=NCCN3C(NC(c3cnc(N)nc3)=O)=N1)c2OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11161111.7 | 2011-04-05 | ||
EP11161111A EP2508525A1 (en) | 2011-04-05 | 2011-04-05 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
PCT/EP2012/055600 WO2012136553A1 (en) | 2011-04-05 | 2012-03-29 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103649091A true CN103649091A (zh) | 2014-03-19 |
CN103649091B CN103649091B (zh) | 2016-06-22 |
Family
ID=43984137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280027509.4A Active CN103649091B (zh) | 2011-04-05 | 2012-03-29 | 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 |
Country Status (42)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107074776A (zh) * | 2014-11-07 | 2017-08-18 | 拜耳制药股份公司 | Copanlisib及其二盐酸盐的合成 |
CN107864625A (zh) * | 2015-03-09 | 2018-03-30 | 拜耳制药股份公司 | 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品 |
CN112930212A (zh) * | 2018-10-17 | 2021-06-08 | 桑多斯股份公司 | 包含左甲状腺素和二羧酸的共晶体 |
CN113260365A (zh) * | 2018-12-27 | 2021-08-13 | 治愈医药社株式会社 | 新型化合物及包含其的用于增强抗癌活性的药学组合物 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
JO3733B1 (ar) | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
CU24400B1 (es) * | 2013-04-08 | 2019-04-04 | Bayer Pharma AG | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas |
CA2915311A1 (en) | 2013-06-14 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Anti-tweakr antibodies and uses thereof |
CN103694319B (zh) * | 2013-12-20 | 2018-02-27 | 深圳翰宇药业股份有限公司 | 一种布舍瑞林的纯化方法 |
EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
MX2017011607A (es) * | 2015-03-09 | 2018-04-10 | Bayer Pharma AG | Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas. |
HUE048111T2 (hu) | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
EP3280448B1 (en) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
WO2017134000A1 (en) | 2016-02-01 | 2017-08-10 | Bayer Pharma Aktiengesellschaft | Copanlisib biomarkers |
KR20180104129A (ko) | 2016-02-01 | 2018-09-19 | 바이엘 파마 악티엔게젤샤프트 | 코판리십 바이오마커 |
MY189113A (en) | 2016-03-02 | 2022-01-26 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
CA3016584A1 (en) * | 2016-03-08 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides |
EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
CA3037626A1 (en) | 2016-09-23 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
JP2020503289A (ja) | 2016-12-14 | 2020-01-30 | ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. | Hsp90標的化コンジュゲート及びその製剤 |
EP3585437B1 (en) | 2017-02-24 | 2022-12-21 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib with anti-pd-1 antibody |
WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
DK3678644T3 (da) * | 2017-09-08 | 2023-07-31 | Bayer Pharma AG | Formuleringer af copanlisib |
WO2019105734A1 (en) | 2017-11-28 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib |
WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
WO2019197269A1 (en) | 2018-04-11 | 2019-10-17 | Bayer Aktiengesellschaft | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer |
WO2020043617A1 (en) | 2018-08-28 | 2020-03-05 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
US20210369724A1 (en) * | 2018-10-16 | 2021-12-02 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
WO2020164997A1 (en) | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2023218032A1 (en) | 2022-05-13 | 2023-11-16 | Synthon B.V. | Solid forms of copanlisib salts |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
WO2008070150A1 (en) * | 2006-12-05 | 2008-06-12 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
WO2010034414A1 (en) * | 2008-09-24 | 2010-04-01 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH588505A5 (und) | 1972-06-08 | 1977-06-15 | Research Corp | |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
TW225528B (und) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
GB0021865D0 (en) | 2000-09-06 | 2000-10-18 | Smithkline Beecham Plc | Novel pharmaceutical |
JP4323793B2 (ja) | 2002-12-16 | 2009-09-02 | キヤノン株式会社 | ズームレンズ及びそれを有する光学機器 |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
CA2713388C (en) * | 2008-01-14 | 2016-03-29 | William Scott | Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
PE20130191A1 (es) | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
JO3733B1 (ar) * | 2011-04-05 | 2021-01-31 | Bayer Ip Gmbh | استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة |
EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
CU24400B1 (es) | 2013-04-08 | 2019-04-04 | Bayer Pharma AG | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas |
US10117874B2 (en) | 2013-12-03 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
MX2017011607A (es) * | 2015-03-09 | 2018-04-10 | Bayer Pharma AG | Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas. |
BR112017019188A2 (pt) | 2015-03-09 | 2018-04-24 | Bayer Pharma Aktiengesellschaft | Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas |
-
2011
- 2011-04-05 EP EP11161111A patent/EP2508525A1/en not_active Withdrawn
-
2012
- 2012-03-27 JO JO201264A patent/JO2958B1/en active
- 2012-03-28 AR ARP120101036A patent/AR085718A1/es not_active Application Discontinuation
- 2012-03-28 UY UY0001033985A patent/UY33985A/es not_active Application Discontinuation
- 2012-03-29 US US14/009,599 patent/US10383876B2/en active Active
- 2012-03-29 CA CA2832123A patent/CA2832123C/en active Active
- 2012-03-29 CU CUP2013000133A patent/CU24208B1/es active IP Right Grant
- 2012-03-29 UA UAA201312858A patent/UA111604C2/uk unknown
- 2012-03-29 PT PT127121044T patent/PT2694508E/pt unknown
- 2012-03-29 PL PL12712104T patent/PL2694508T3/pl unknown
- 2012-03-29 EA EA201391470A patent/EA023646B1/ru not_active IP Right Cessation
- 2012-03-29 ES ES12712104.4T patent/ES2529653T3/es active Active
- 2012-03-29 AU AU2012238891A patent/AU2012238891B2/en active Active
- 2012-03-29 WO PCT/EP2012/055600 patent/WO2012136553A1/en active Application Filing
- 2012-03-29 MA MA36288A patent/MA35014B1/fr unknown
- 2012-03-29 AP AP2013007219A patent/AP3709A/en active
- 2012-03-29 CN CN201280027509.4A patent/CN103649091B/zh active Active
- 2012-03-29 PE PE2013002186A patent/PE20141038A1/es active IP Right Grant
- 2012-03-29 JP JP2014503079A patent/JP5763834B2/ja active Active
- 2012-03-29 SI SI201230138T patent/SI2694508T1/sl unknown
- 2012-03-29 SG SG2013071501A patent/SG193595A1/en unknown
- 2012-03-29 EP EP12712104.4A patent/EP2694508B1/en active Active
- 2012-03-29 BR BR112013025549A patent/BR112013025549A2/pt not_active Application Discontinuation
- 2012-03-29 MY MYPI2013701860A patent/MY169452A/en unknown
- 2012-03-29 DK DK12712104.4T patent/DK2694508T3/en active
- 2012-03-29 MX MX2013011583A patent/MX336057B/es unknown
- 2012-03-29 ME MEP-2015-16A patent/ME02021B/me unknown
- 2012-03-29 RS RS20150077A patent/RS53811B1/en unknown
- 2012-03-29 KR KR1020137028852A patent/KR101937501B1/ko active IP Right Grant
- 2012-03-30 TW TW101111580A patent/TWI549954B/zh active
- 2012-03-30 TW TW105122778A patent/TWI592158B/zh active
-
2013
- 2013-09-20 ZA ZA2013/07105A patent/ZA201307105B/en unknown
- 2013-09-29 IL IL228561A patent/IL228561A/en active IP Right Grant
- 2013-10-03 TN TNP2013000401A patent/TN2013000401A1/fr unknown
- 2013-10-04 DO DO2013000223A patent/DOP2013000223A/es unknown
- 2013-10-04 CO CO13236625A patent/CO6781534A2/es not_active Application Discontinuation
- 2013-10-04 CR CR20130511A patent/CR20130511A/es unknown
- 2013-10-04 CL CL2013002870A patent/CL2013002870A1/es unknown
- 2013-10-04 GT GT201300234A patent/GT201300234A/es unknown
- 2013-11-04 EC ECSP13013006 patent/ECSP13013006A/es unknown
-
2014
- 2014-09-16 HK HK14109333.1A patent/HK1195907A1/zh unknown
-
2015
- 2015-02-04 HR HRP20150138TT patent/HRP20150138T1/hr unknown
- 2015-02-12 SM SM201500037T patent/SMT201500037B/xx unknown
- 2015-02-19 CY CY20151100174T patent/CY1116231T1/el unknown
- 2015-04-28 JP JP2015091455A patent/JP5826961B2/ja active Active
-
2016
- 2016-01-07 US US14/990,350 patent/US9636344B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
WO2008070150A1 (en) * | 2006-12-05 | 2008-06-12 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
WO2010034414A1 (en) * | 2008-09-24 | 2010-04-01 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107074776A (zh) * | 2014-11-07 | 2017-08-18 | 拜耳制药股份公司 | Copanlisib及其二盐酸盐的合成 |
CN107074776B (zh) * | 2014-11-07 | 2021-02-02 | 拜耳制药股份公司 | Copanlisib及其二盐酸盐的合成 |
CN107864625A (zh) * | 2015-03-09 | 2018-03-30 | 拜耳制药股份公司 | 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品 |
CN112930212A (zh) * | 2018-10-17 | 2021-06-08 | 桑多斯股份公司 | 包含左甲状腺素和二羧酸的共晶体 |
CN113260365A (zh) * | 2018-12-27 | 2021-08-13 | 治愈医药社株式会社 | 新型化合物及包含其的用于增强抗癌活性的药学组合物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103649091B (zh) | 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 | |
CN102858768B (zh) | 取代三唑并吡啶 | |
CN102762557B (zh) | 三唑并吡啶 | |
CN103443100B (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的取代的6-咪唑并吡嗪 | |
CN102413831B (zh) | 取代的咪唑并喹喔啉 | |
CN103370322B (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪 | |
CN103764656A (zh) | 杂环基氨基咪唑并哒嗪 | |
CN103687858A (zh) | 作为mknk1激酶抑制剂的氨基取代的咪唑并哒嗪 | |
CN102596932A (zh) | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 | |
CN104797585A (zh) | 氨基咪唑并哒嗪 | |
CN103429591A (zh) | 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪 | |
CN103717604A (zh) | 取代的氨基咪唑并哒嗪 | |
CN105008363A (zh) | 作为mknk-1激酶抑制剂的酰氨基咪唑并哒嗪 | |
CN103228274A (zh) | 包含取代的n-(2-芳基氨基)芳基磺酰胺的组合 | |
CN105008364A (zh) | 取代的咪唑并哒嗪 | |
CN103415518A (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪 | |
CN103403006B (zh) | 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的6-硫代-取代的咪唑并吡嗪 | |
CN103582632A (zh) | 取代的苯并咪唑 | |
CN102834100A (zh) | 新型pan-CDK抑制剂用于治疗肿瘤的用途 | |
CN104284896A (zh) | 取代的咪唑并哒嗪 | |
CN107108636A (zh) | 6‑羟基苯并呋喃基‑和6‑烷氧基苯并呋喃基‑取代的咪唑并哒嗪 | |
CN103282351A (zh) | 取代的苯氧基吡啶 | |
NZ616198B2 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | |
CN103649087A (zh) | 取代的咪唑并吡啶及其中间体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1195907 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1195907 Country of ref document: HK |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: On the Rhine River, Germany Patentee after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Germany Patentee before: BAYER INTELLECTUAL PROPERTY GmbH |